-
Lepu Medical: mergers and acquisitions more than 30 times only to set up a "heart" of hope
Time of Update: 2021-02-27
Lepu Medical took several years of extended mergers and acquisitions to acquire the cardiovascular field of overweight pounds, heavy weights, sub-segmented leading drugs, from the technical and market dimensions, to further build a "moth." fully biodegradable vascular stent (NeoVas) is a technological revolution in the field of cardiovascular interventional therapy at Lepu Medical.
-
Chuanmei Medical A-share IPO will challenge the GEM IPO record
Time of Update: 2021-02-27
on the eve of the 2015 Chinese stock market disaster, Myer International launched the privatization of American Depositarius shares listed on the New York Stock Exchange and de-listed them from the United States in March 2016 at a cost of approximately $2.46 billion, according to the filing.
-
Net profit down 60% deduction non-net profit increased by nearly 40% Temple of Heaven biological transformation pain period?
Time of Update: 2021-02-27
According to the announcement disclosed by Tiantan Bio, in the first three quarters of 2017, Tiantan Bio transferred its 100% stake in Beijing Beisheng Research Biological Products Co., Ltd. and 51% stake in Changchun Jian Biological Products Co., Ltd., achieving an investment income (after tax) of 758 million yuan, mainly affected by this, the company's operating profit, total profit, net profit attributable to shareholders of listed companies, basic earnings per share decreased significantly in the first three quarters of 2018.
-
Beda Pharmaceuticals listed two years of continuous decline in performance, trapped in the "one drug, one big" dilemma?
Time of Update: 2021-02-27
third-quarter results showed that Bayda Pharmaceuticals reported revenue of 928 million yuan in the first three quarters, up 20.74 percent from a year earlier, while net profit attributable to shareholders of listed companies was 148 million yuan, down 27.37 percent from a year earlier.
-
Shanghai built the largest medical emergency system Emergency Sub-stations increased by 32
Time of Update: 2021-02-27
City Health and Health Commission recently released the latest data: through three consecutive years of "municipal government practical projects", the city added 32 first aid stations.
Through the implementation of the "municipal government practical project" for three consecutive years, for the city-wide first aid blank spots, continue to strengthen the network.
-
Changsheng Bio's vice chairman was sued by Societe Generale for 630 million yuan
Time of Update: 2021-02-27
July 23rd, ST Changsheng announced that Zhang hao, a shareholder of the company, had made three supplementary pledges for his 73.3624 million shares, with the rights per capita being Henyep Securities.
-
The world's market capitalization of more than a trillion dollars Apple layout medical speed up
Time of Update: 2021-02-27
Apple shares were trading at $207.39 in the early hours of August 3, Beijing time, with a market capitalisation of $101.678 billion.
-
Connbey's first three-quarter results exceeded last year's full-year stake in the company increased to 4.38 percent
Time of Update: 2021-02-27
For The first three quarters of this year to achieve a substantial increase in revenue and stable growth in net profit, the company's chairman Hu Jiqiang said, mainly due to the promotion and implementation of large-brand large-variety projects, at the same time, launched in February this year, science and technology innovation-driven development projects, both to enhance the competitiveness of the company's existing products, but also for the company's future business development laid the foundation.
-
Domestic PD-1 was approved for new adaptive diseases major pharmaceutical companies must compete for the track
Time of Update: 2021-02-24
present, in addition to Junshi Bio, Hengrui's Karelli Zhu single anti-nasopharyngeal cancer after-line treatment and first-line treatment of new adaptive disorders have also been declared on the market, is in the review and approval stage.
-
Lilly and Rigel have agreed to a $960 million RIPK1 inhibitor partnership
Time of Update: 2021-02-24
On Thursday, Lilly announced an exclusive licensing agreement with Rigel Pharmaceuticals, in which the two companies will jointly develop Rigel's RIPK1 inhibitor R552 and will be responsible for the commercialization of the therapy for all adaptations, including autoimmune and inflammatory diseases.
-
The State Department has issued new rules on health care! These acts should be severely punished!
Time of Update: 2021-02-24
On February 20th, the Chinese government issued the Regulations on the Supervision and Administration of the Use of Medical Security Funds (hereinafter referred to as the Regulations on Administration
-
General Administration of Market Supervision: Third-party nucleic acid testing institutions may not use service packages and other means to force bundle charges
Time of Update: 2021-02-24
Pharmaceutical Network February 8th, February 7th, the General Office of the General Administration of Market Supervision announced the "Notice on doing a good job in the near-term price supervision c
-
From drug-free to multiple treatments, 34 clinically urgently needed new drugs have been approved
Time of Update: 2021-02-24
addition, NMPA has approved a number of clinically urgent overseas drugs to bring innovative therapies to patients with multiple types of diseases.
-
Heavy! The State Council issued a good document on the interests of Chinese medicine and respected the law of research and development of Chinese medicine
Time of Update: 2021-02-24
(The State Administration of Traditional Chinese Medicine, the National Development and Reform Commission, the National Health And Health Commission, the Ministry of Industry and Information Technology, the State Drug Administration is responsible for) to improve the Western medicine study of Chinese medicine system from 2021, the Chinese medicine curriculum as a compulsory undergraduate clinical medicine major and graduation internship content, increase the course time.
-
Biosynthic drug policy landing: can not automatically extratrot reference drug all adaptive
Time of Update: 2021-02-24
February 19th, February 18th, the first working day after the National Drug Administration Drug Review Center (CDE) official website issued the "Biosyspole Drug Similarity Evaluation and Adaptation Ex
-
Hong Kong Special Administrative Region Government: The kosing vaccine is approved for emergency use in accordance with regulations
Time of Update: 2021-02-24
THE SAR Government means that the advisory committee's examination of the data and the Government's approval process is rigorous, comprehensive and meets the relevant requirements under all the Regulations, which is no different from the procedure for approving the previous new crown vaccine approved for emergency use in Hong Kong.
-
Why is it so difficult to register? Online medical appointments to prevent "Yellow" rob number
Time of Update: 2021-02-24
Medical Network February 8th, Ms. Zhou, a reader living in a central city, recently wrote a letter about her troubles. , she had a stomach atrial condition and went to a local hospital, where her cond
-
The State Drug Administration identified the second batch of 72 key laboratories, such as in-body diagnostic reagent quality research and evaluation
Time of Update: 2021-02-24
February 2021, the State Drug Administration identified and announced the second batch of 72 key laboratories, such as in-body diagnostic reagent quality research and evaluation.
, improving the drug regulatory authority's ability to respond to major public health emergencies has become an important consideration in the comprehensive evaluation.
-
Take stock | more than 20 new Chinese drugs that will be eligible for FDA orphan drugs by 2020
Time of Update: 2021-02-24
1, Drugs: APG-2575 Research and Development Enterprise: AXA Pharmaceutical Treatment Diseases: Fahrenheit GlobulinEmia (WM), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) APG-2575 is A new oral Bcl-2 selective small molecule inhibitor developed by Yasheng Pharmaceuticals restores the mechanism of procedural death of tumor cells (apoptosis) by selectively inhibiting Bcl-2 protein, thereby killing tumors and intended to be used to treat a variety of blood malignancies.
-
Latest! The price of Chinese medicine is generally rising, and the quality is improving
Time of Update: 2021-02-24
Industry generally believe that in the short term, the implementation of the new pharmacopeia may stimulate the price of Chinese herbal medicines, but in the long run, more stringent quality standards, will undoubtedly regulate the entire Chinese herbal medicine market more healthy development.
